key: cord-0013200-1j2140ol
authors: Takezako, Naoki; Shibayama, Hirohiko; Handa, Hiroshi; Hagiwara, Shotaro; Ozaki, Shuji; Suzuki, Kenshi; Kosugi, Hiroshi; Ri, Masaki; Sugiura, Isamu; Choi, Ilseung; Miyamoto, Toshihiro; Iida, Shinsuke
title: Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
date: 2020-10-10
journal: Int J Hematol
DOI: 10.1007/s12185-020-03013-6
sha: 0aaae038a2eb91b89a08cd6b1200fb9955b15aa9
doc_id: 13200
cord_uid: 1j2140ol

A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m(2) vs. twice-weekly Kd 20/27 mg/m(2) based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm, n = 14) were randomized in A.R.R.O.W. In the Japanese subgroup of A.R.R.O.W., median PFS was 14.8 months (95% confidence interval [CI], 7.5–not evaluable [NE]) and 9.7 months (95% CI, 3.8–NE) in the once- and twice-weekly arms, respectively. The overall response rate (ORR) was 73.1% (19/26; 95% CI, 52.2–88.4) and 57.1% (8/14; 95% CI, 28.9–82.3) in each arm. The adverse events (AEs) incidence was 100% in both arms. Grade ≥ 3 AE incidence was 80.8% (21/26) and 78.6% (11/14) in each arm. Two fatal treatment-related AEs (acute lung injury and acute respiratory distress syndrome) occurred in the once-weekly arm. In exploratory unadjusted analyses of A.R.R.O.W. (once-weekly Kd 20/70 mg/m(2)) vs. ENDEAVOR (twice-weekly Kd 20/56 mg/m(2)), median PFS was 14.8 months vs. NE due to not yet being reached, and ORR was 73.1% (19/26) vs. 42.9% (3/7). In the Japanese subgroup, once-weekly Kd tended to improve ORR vs. twice-weekly Kd. Results from A.R.R.O.W. tended to be consistent with results from ENDEAVOR. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12185-020-03013-6) contains supplementary material, which is available to authorized users.

Multiple myeloma (MM) comprises approximately 10% of all hematological malignancies. In Japan, the annual incidence and 5-year prevalence rates of MM were reported to be 1.3-5.4 and 9.7 per 100,000 persons, respectively [1] . Given the better understanding of the disease and the advent of new treatments during the past decades, the overall survival (OS) of patients with MM has remarkably increased m 2 , and both treatment schedules had comparable safety. Herein, we describe the results of the Japanese subgroup of the A.R.R.O.W. study [13] . To date, no clinical studies have compared once-weekly Kd 20/70 mg/m 2 with twiceweekly Kd 20/56 mg/m 2 . To compare the outcomes of onceweekly Kd 20/70 mg/m 2 vs. twice-weekly Kd 20/56 mg/ m 2 , we compared data from subjects from the A.R.R.O.W. study who were treated with once-weekly Kd 20/70 mg/m 2 with that of subjects from the ENDEAVOR study who were treated with twice-weekly Kd 20/56 mg/m 2 [7, 8] . Owing to key differences in the eligibility of subjects from the ENDEAVOR and A.R.R.O.W. studies in terms of prior number of therapies, refractoriness to the most recent therapy, and prior use of a proteasome inhibitor and immunomodulatory drugs, we conducted an exploratory unadjusted analysis using subjects from the ENDEAVOR study whose criteria met that of both the overall and Japanese populations of the A.R.R.O.W. study.

Detailed inclusion and exclusion criteria for the A.R.R.O.W. study have been previously published [13] . Briefly, eligible subjects were men and women ≥ 18 years of age with RRMM, who had received two to three prior regimens, including a proteasome inhibitor and an immunomodulatory drug. Subjects were required to be refractory to the most recent therapy (including bortezomib or ixazomib) and have measurable disease defined by ≥ 1 of the following (assessed within 21 days before randomization): serum M-protein ≥ 0.5 g/dL, urine M-protein ≥ 200 mg/24 h, or in subjects without detectable serum or urine M-protein, serum-free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio (SFLC kappa lambda ratio < 0.22 or > 1.52).

Key exclusion criteria were as follows: having received cytotoxic chemotherapy 28 days or radiotherapy 7 days prior to randomization; presence of Waldenström macroglobulinemia; MM of the immunoglobulin M subtype; polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome; plasma cell leukemia; myelodysplastic syndrome; history of or current amyloidosis; second malignancy in the past 5 years; grade 3 or worse neuropathy in the 14 days before randomization; active infection; or severe cardiac disease.

Ethical approval by the institutional review boards was obtained, and the study was conducted in accordance with the International Council for Harmonisation Good Clinical Practice regulations/guidelines and the Declaration of Helsinki. All patients provided written informed consent. The A.R.R.O.W. study was registered at ClinicalTrials.gov under the identifier NCT02412878.

The details of the study design have been published [13] . The A.R.R.O.W. study was a randomized, open-label, phase 3 trial. Eligible subjects were randomly assigned in a 1:1 ratio through an interactive voice response system or interactive web response system to receive either once-weekly Kd 20/70 mg/m 2 or twice-weekly Kd 20/27 mg/m 2 . Eligible subjects were stratified at the time of randomization based on the International Staging System (stage 1 vs. stages 2 or 3), refractory to bortezomib treatment (yes vs. no), and age (< 65 vs. ≥ 65 years) and were randomly assigned to treatment on a blocked randomization scheme.

Kd was administered in 28-day cycles. All cycles started 28 days (± 2 days) after the start of the previous cycle. Dexamethasone 40 mg was administered for at least 30 min on Days 1, 8, and 15 in both treatment arms. Dexamethasone on Day 22 was taken orally, whenever possible, and was only administered during Cycles 1 to 9. Treatment continued until disease progression or unacceptable toxic effects. Dose reductions of carfilzomib were permitted to manage adverse events (AEs). Antiviral prophylaxis (valacyclovir or an equivalent antiviral agent) was recommended to prevent herpes zoster reactivation during treatment and a proton pump inhibitor was recommended to prevent peptic ulcer disease.

To assess response and disease progression, we used modified versions of the International Myeloma Working Group-Uniform Response Criteria [14] and the Consensus recommendations of the International Myeloma Workshop Consensus Panel 1 [15] . Hematological and serum chemistry assessments were conducted at a central laboratory.

The primary study endpoint of the A.R.R.O.W. study was PFS (defined as the time from randomization until disease progression or death due to any cause), which was compared between arms in the intent-to-treat population. The secondary endpoints were ORR (defined as the proportion of patients who achieved a partial response, very good partial response, complete response [CR], or stringent complete response [sCR] according to International Myeloma Working Group Uniform Response Criteria), best overall response, duration of overall response, clinical benefit rate (CBR), and OS (defined as the time from randomization to death due to any cause). To compare two dosing regimens (onceweekly Kd 20/70 mg/m 2 and twice-weekly Kd 20/56 mg/ m 2 ), we conducted an exploratory unadjusted analysis using data from a subgroup of patients from the A.R.R.O.W. study who were treated with once-weekly Kd 20/70 mg/m 2 and a subgroup of patients from the ENDEAVOR study who were treated with twice-weekly Kd 20/56 mg/m 2 . The following key inclusion criteria that were similar between the two studies were identified: patients who had two to three prior therapies, were refractory to the most recent therapy and had prior use of a proteasome inhibitor and immunomodulatory drugs. Comparisons were made between the overall populations of the A.R.R.O.W. (once-weekly Kd 20/70 mg/m 2 ) and ENDEAVOR (twice-weekly Kd 20/56 mg/m 2 ) studies; the overall populations of A.R.R.O.W. and ENDEAVOR who met the above criteria; and the Japanese subgroups of A.R.R.O.W. and ENDEAVOR who met the above criteria.

Safety endpoints of the A.R.R.O.W. study were AEs and any abnormalities in vital signs, general laboratory tests (blood chemistry, hematology, coagulation, and urinalysis), and 12-lead electrocardiography.

AEs were recorded for at least 30 days after the last administered dose and were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).

Details of the statistical methods, definition of pre-planned analysis populations, and primary/secondary analyses have already been described in the interim report of the ARROW study [13] . For PFS and OS, the median time to event per each treatment arm was derived using the Kaplan-Meier method. The duration of response was summarized descriptively using the Kaplan-Meier method in patients who achieved at least a partial response. In this A.R.R.O.W. study, the log-rank test was used for between-group comparisons (once weekly vs. twice weekly arms), and the corresponding HR and 95% CI were estimated using a Cox proportional hazards model stratified by the randomization stratification factors. The Cochran-Mantel-Haenszel test was used to analyze stratified binary data (ORR).

The present analyses were subgroup analyses of the intent-to-treat population and not powered nor adjusted for multiplicity. We conducted an exploratory unadjusted analysis comparing data between the overall populations of the A.R.R.O.W. (once-weekly Kd 20/70 mg/m 2 ) and ENDEAVOR (twice-weekly Kd 20/56 mg/m 2 ) studies, and between the overall populations of A.R.R.O.W. and ENDEAVOR and the Japanese subgroups of A.R.R.O.W. and ENDEAVOR who had received two to three prior therapies, were refractory to the most recent therapy, and had received prior proteasome inhibitor and immunomodulatory drugs, and compared these subgroups numerically. All statistical analyses were conducted using SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA).

Patient disposition is shown in Fig. 1 . Of the 47 Japanese patients screened, 40 were randomly assigned to the treatment arms: 26 patients were assigned to the once-weekly arm and 14 patients to the twice-weekly arm. All patients in each arm received Kd. In the once-weekly arm, 18 patients discontinued the study drug: nine discontinued for AEs; seven discontinued for disease progression, and one patient each discontinued for subject request and physician decision. In the twice-weekly arm, 10 patients discontinued the study drug: eight discontinued for disease progression and two for AEs.

In the Japanese subgroup, patients in the once-weekly and twice-weekly arms were generally comparable in terms of demographic and disease characteristics (Table 1) . Overall, as well as in both arms, slightly more than half of the patients were male (53.8% and 57.1%, respectively). Overall, patients had a median age of 67.0 (35, 80) years. In the once-weekly arm vs. twice-weekly arm, a larger proportion of patients (46.2% vs. 35.7%) were between 65 and 74 years of age, while in the twice-weekly arm vs. once-weekly arm, a larger proportion of patients (42.9% vs. 26.9%) were between 18 and 64 years of age. Over 60% of patients overall and in both arms had an Eastern Cooperative Oncology Group Performance Status of 0. In the once-weekly arm, 61.5% of patients had an unknown risk determined by fluorescence in situ hybridization, followed by 19.2% each for high and standard risk, while in the twice-weekly arm, half of the patients had an unknown risk status, but 28.6% were at high risk, and 21.4% were at standard risk. All patients had received either two or three prior treatment regimens. Patients in the once-weekly arm received a median of 2.5 prior treatments, and those in the twice-weekly arm received a median of 2.4 prior treatments. Prior treatment regimens included bortezomib (100%), lenalidomide (92.5%), or thalidomide (27.5% 

The median PFS was 14.8 (95% CI 7.5, not evaluable [NE] ) months in the once-weekly arm and 9.7 (95% CI 3.8, NE) months in the twice-weekly arm (Fig. 2a) . The HR of progression or death for the once-weekly vs. twice-weekly arm was 0.542 (95% CI 0.162, 1.810). Table 2 provides a summary of the efficacy measures. Three of 26 patients in the once-weekly arm (11.5%) and none of 14 patients in the twice-weekly arm achieved CR, while no patients in either arm achieved sCR. The ORR was 73.1% (19/26) in the once-weekly arm, and 57.1% (8/14) in the twice-weekly arm (Fig. 2B) . The percentage of patients with very good partial response or better was 42.3% (11/26) in the once-weekly arm and 28.6% (4/14) in the twice-weekly arm. The median duration of response was 15.1 (11.1, NE) months in the once-weekly arm and NE (2.8, NE) months in the twice-weekly arm. The CBR was 84.6% (22/26) in the once-weekly arm and 57.1% (8/14) in the twice-weekly arm. OS was NE in both arms (Table 2 ).

We conducted an exploratory analysis comparing the efficacy results (Table 3) W. and ENDEAVOR who met the following criteria: had two to three prior therapies, were refractory to the most recent therapy and had prior use of a proteasome inhibitor and immunomodulatory drugs; and (iii) the Japanese subgroups of A.R.R.O.W. and ENDEAVOR who met the above criteria. The median PFS of the overall population of A.R.R.O.W. was 11.3 months, and that of the overall population of ENDEAVOR was 18.7 months. For the overall population in A.R.R.O.W. and ENDEAVOR who met the above criteria, the PFS was 11.2 months and 7.5 months, respectively, while for the Japanese subgroups from A.R.R.O.W. and ENDEAVOR who met the above criteria, the median PFS was 14 

In the Japanese subgroup of the A.R.R.O.W study, the incidence of AEs of any grade was 100% in both arms, with 80.8% (21/26) of grade ≥ 3 AEs in the once-weekly arm and 78.6% (11/14) in the twice-weekly arm. Discontinuation of carfilzomib was attributable to AEs in 34.6% (9/26) of the cases in the once-weekly arm and 14.3% (2/14) in the twice-weekly arm. These AEs leading to discontinuation in the once-weekly arm were thrombotic microangiopathy (TMA), cardiac failure, cardiac failure acute (2 patients), cardiac failure congestive, pyrexia, pneumonia haemophilus, ejection fraction decreased, blood creatinine increased, C-reactive protein increased, acute lung injury (ALI; 2 patients), acute respiratory distress syndrome (ARDS), and hypertension. Those in the twice-weekly arm were cardiac failure and myelodysplastic syndrome. The two AEs observed in ≥ 2 patients in the Japanese subgroup, cardiac failure acute and ALI, were not observed in other patients in the overall population in the once-weekly arm.

The incidence of treatment-related AEs was 92.3% (24/26) in the once-weekly arm and 92.9% (13/14) in the twice-weekly arm (Table 4 ). There were two fatal treatmentrelated AEs, ALI and ARDS, both of which occurred in the once-weekly arm. Regarding the ALI case, this AE occurred during Cycle 18 (Day 484). Detailed information on the case could not be obtained. In the ARDS case, the AE occurred during Cycle 2 (Day 55). This patient had pneumonia secondary to influenza before developing ARDS.

The incidences of serious AEs were 61.5% (16/26) and 28.6% (4/14) in the once-weekly and twice-weekly Kd arms, respectively. Serious AEs that occurred with a frequency greater than 5% in the once-weekly Kd arm were tumor lysis syndrome (11.5%, 3/26), cardiac failure acute (7.7%, 2/26), pneumonia (7.7%), and acute lung injury (7.7%). In the twice-weekly Kd arm, serious AEs that occurred with a frequency greater than 5% were cardiac failure (7.1%, 1/14), cholecystitis acute (7.1%), pneumonia (7.1%), osteomyelitis (7.1%), and acute kidney injury (7.1%). Table 5 shows the AEs overall and grade 3 or higher that occurred in more than 10% of subjects. Of any grade, the AEs with the highest frequency in the once-weekly and twice-weekly arms were platelet count decreased (38.5%, 10 

The main objectives of this subgroup analysis were to examine the efficacy and safety of once-weekly and twice-weekly Kd regimens in the Japanese subgroup of the A.R.R.O.W. study population [13] . Additionally, we conducted an exploratory unadjusted analysis to compare the present results with those of a subgroup of patients from ENDEAVOR [7, 8] .

The main efficacy findings of this analysis were that once-weekly Kd 20/70 mg/m 2 tended to improve median PFS (14.8 months) and ORR (73.1%, 19/26) compared with the PFS (9.7 months) and ORR (57.1%, 8/14) with the twice-weekly Kd 20/27 mg/m 2 regimen in Japanese RRMM patients. Furthermore, the ORR for both the once-weekly Kd 20/70 mg/m 2 and twice-weekly Kd 20/27 mg/m 2 regimens tended to be comparable to those observed in the interim analysis of A.R.R.O.W [13] . and to those observed with the once-weekly Kd 20/70 mg/m 2 administration in the phase 1/2 CHAMPION-1 study (ORR = 77%, 80/104) [11] and a Japanese study using Kd weekly dosing in a similar patient population (83.3%, 5/6) [12] .

Regarding the safety profile of the Japanese subgroup from A.R.R.O.W., the overall incidence of grade ≥ 3 AEs was comparable between the once-weekly Kd 20/70 mg/m 2 (80.8%, 21/26) and twice-weekly Kd 20/27 mg/m 2 (78.6%, 11/14) arms. However, higher rates of carfilzomib treatment discontinuation, dose reduction, serious AEs, and fatal AEs were reported for once-weekly Kd 20/70 mg/m 2 compared with twice-weekly Kd 20/27 mg/m 2 . Those higher ratios observed in the once-weekly Kd 20/70 mg/m 2 arm were most likely attributed to the different evaluation periods: median durations of the study drug administration in the Japanese subgroups were 55.8 weeks in the once-weekly Kd 20/70 mg/m 2 arm and 37.3 weeks in the twice-weekly Kd 20/27 mg/m 2 arm. As compared to Japanese patients treated with the twice-weekly Kd 20/56 mg/m 2 for 154 days in the ENDEAVOR study, Japanese patients treated with the once-weekly Kd 20/70 mg/m 2 for the same 154-day period exhibited similar incidences of AEs, including AEs with grade 3 or more, fatal AEs, serious AEs, and AEs leading to treatment discontinuation. Therefore, incidence rates of these AEs during a particular period in the once-weekly Kd 20/70 mg/m 2 arm may be comparable to those with the other treatments.

Two fatalities occurred in the once-weekly Kd arm; one fatality due to ALI and the other due to ARDS. Notably, such events occurred only in the Japanese subgroup. Unfortunately, the details and information regarding the ALI case were limited. However, the patient who presented ARDS had an underlying respiratory condition (pneumonia secondary to influenza virus) that may have predisposed the patient to develop respiratory complications. Regarding cardiac failure in relation to carfilzomib treatment, no fatal cardiac failure event was reported in Japanese patients, but two (7.7%, 2/26) and one (7.1%, 1/14) grade 3 or higher cardiac failure events were reported in the once-weekly and twice-weekly arms, respectively. One patient in the Japanese subgroup from A.R.R.O.W. receiving once-weekly Kd 20/70 mg/m 2 presented TMA. Furthermore, TMA was also reported in the phase 1 study that assessed the tolerability of Kd 20/70 mg/ m 2 in Japanese patients [12] . Although the occurrence of TMA is infrequent, once TMA occurs, it can become a serious event. Patients who develop TMA during carfilzomib CI confidence interval, Kd carfilzomib (Kyprolis) plus dexamethasone, NE not estimable a Best overall response is defined as a subject's best response during the study b Median and percentiles were estimated using the Kaplan-Meier method. Corresponding CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation c Clinical benefit is defined as achieving a best overall response of MR, PR, VGPR, CR or sCR d Clopper-Pearson interval e Median was estimated using the Kaplan-Meier method. Corresponding CIs were estimated using the method by Klein and Moeschberger treatment require careful attention and prompt management, including plasmapheresis, which may improve the outcome of these patients. Still, the present findings reinforce the need to closely monitor RRMM patients receiving Kd for ALI/ ARDS, cardiac failure, and TMA during treatment. Nonetheless, the overall benefit-risk profile of once-weekly Kd 20/70 mg/m 2 was favorable among Japanese patients. Exploratory analyses of the Japanese subgroup from the A.R.R.O.W. and ENDEAVOR studies (i.e., patients who had received two to three prior therapies, were refractory to the most recent therapy, and with prior use of a proteasome inhibitor and immunomodulatory drugs), suggested that the efficacy of carfilzomib (ORR 73.1% [19/26] and 42.9% [3/7] and median PFS 14.8 months and NE in the Japanese subgroups from A.R.R.O.W. and ENDEAVOR, respectively) tended to be similar between trials. Selected overall patient populations from A.R.R.O.W. and ENDEAVOR also showed comparable efficacy, consistently with a recent report [16] . As this was an exploratory comparison and not a head-to-head comparison, it is difficult to conclusively compare the clinical benefits of once weekly Kd 20/70 mg/ m 2 and twice weekly Kd 20/56 mg/m 2 . In the ENDEAVOR trial, the median PFS of Asian patients was longer with Kd (14.9 months) than with Vd (8.8 months), and the ORR was 80.4% (45/56) vs. 70.2% (40/57), respectively [17] . Similarly, the median PFS of Asian patients in A.R.R.O.W. was longer for once-weekly (16.0 months) than for twice-weekly dosing (8.4 months), and the ORR was 76.7% (23/30) compared with 53.3% (8/15), respectively [17] .

A recent analysis of patient-reported outcomes comparing once-weekly Kd 20/70 mg/m 2 and twice-weekly Kd 20/27 mg/m 2 in the A.R.R.O.W. study in terms of convenience, satisfaction, and health-related quality of life of RRMM patients [18] described that patients in the once-weekly arm reported significantly greater convenience (odds ratio [OR], 4.98; 95% CI 2.54-9.77; p < 0.001) and satisfaction (OR, 2.41; 95% CI 0.97-6.01; p = 0.059) than those in the twice-weekly arm. Furthermore, the time to deterioration was longer for those in the once-weekly arm compared with the twice-weekly arm. Thus, the present findings and those of the above report further support the convenience of the once-weekly regimen (studied in A.R.R.O.W.).

The main limitations of the study were the small sample of Japanese patients and the open-label design. Additionally, selection bias could not be avoided. As the number of patients in the Japanese cohort is small, the efficacy and safety data should be considered as purely descriptive, and limited conclusions can be drawn from comparing individual AEs. Furthermore, the cross-trial comparison with ENDEAVOR [7] was an exploratory comparison, not a head-to-head comparison, and it was not adjusted. While we are aware of the limitations of this type of comparison, we considered this analysis would be of value as there are limited published data from clinical trials comparing onceweekly Kd 20/70 mg/m 2 and twice-weekly Kd 20/56 mg/m 2 , both of which have been approved in Japan.

In 

Epidemiology and burden of multiple myeloma in Japan: a systematic review

Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop

Clinical profiles of multiple myeloma in Asia-an Asian myeloma network study

Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma

Proteasome inhibitors-molecular basis and current perspectives in multiple myeloma

Japanese package insert

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised

Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: a phase 1/2 study

CHAMPION-1: a phase 1/2 study of once weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: a phase 1 and PK/ PD trial

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma

International uniform response criteria for multiple myeloma

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR

Outcomes for Asian patients with multiple myeloma receiving once-or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs twice-weekly 27 mg/m2 carfilzomib (randomized A

The authors wish to thank all study participants and their families and all study sites and investigators. We thank the contributions and critical review of the manuscript by Jiafen Shu and Anita Zahlten-Kuemeli (Amgen, Thousand Oaks), as well as that from Yutaro Ueno (Ono Pharmaceutical). We also acknowledge the statistical support of Toshiaki Ozaki (Ono Pharmaceutical, Osaka). The authors thank Keyra Martinez Dunn, MD of Edanz Medical Writing, for providing medical writing support, which was funded by Ono Pharmaceutical through EMC K.K. in accordance with Good Publication Practice (GPP3) guidelines (https ://www.ismpp .org/gpp3). This research was funded by Amgen Inc. and Ono Pharmaceutical. Ono Pharmaceutical supported this manuscript using the data provided by Amgen.